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Local wound infiltration with liposomal bupivacaine 
decreases post-cesarean pain scores 
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Department of Obstetrics and Gynecology, Wright State University Boonshoft School of Medicine, Dayton, OH 
ABSTRACT & INTRODUCTION 
• Surgical patients are routinely prescribed opioid 
analgesics that are strongly associated with drug 
overdose deaths. 
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• Liposomal bupivacaine is a long-acting local 
anesthetic that received FDA approval in 2011 for 
local surgical site infiltration to promote post-
operative analgesia 
• This anesthetic has demonstrated an 
improvement in post-operative pain control in 
various surgical realms, indicating a decreased 
need for opiates and subsequently decreased 
risks. However, few studies have investigated its 
use at the time of cesarean delivery. 
METHODS 
• Retrospective study of patients who underwent 
cesarean delivery from May-December 2019 at 
Miami Valley Hospital in Dayton, OH 
• Inclusion criteria: Age 18-45, BMI <60 
• Liposomal bupivacaine group (n=57) received 
intraoperative liposomal bupivacaine in 
addition to standard of care analgesics, which 
includes intrathecal or epidural morphine 
• Control group (n= 59) underwent C section 
within 1 week of LBG counterpart and within 3 
weeks of gestational age of LBG counterpart 
• Statistical analysis was completed using IBM 
SPSS Statistics 
PRIMARY OUTCOMES 
• Patient opiate use in morphine-equivalent 
doses (MED) from 24-48 hours post-
operatively 
• Patient pain ratings via 11-point Likert Scale 
averaged every 12 hours 
RESULTS 
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Patients who received liposomal bupivacaine 
during C-section had significantly lower pain
scores 0-24 hours after surgery. 
CONCLUSIONS & FUTURE DIRECTIONS 
• Confounding factors include differences between 
post-operative opiate pain medication 
administration by nursing care which could lead 
to lack of significant differences in opiate use. 
• Future directions include a prospective 
randomized control trial emphasizing patient and 
healthcare worker education on post-operative 
analgesic usage. Additional studies should 
assess differences between liposomal and 
systemic bupivacaine 
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